Literature DB >> 21388336

Therapeutic targeting of tumor-stroma interactions.

Stephen Hiscox1, Peter Barrett-Lee, Robert I Nicholson.   

Abstract

INTRODUCTION: Cancers exist within a complex microenvironment populated by diverse cell types within a protein-rich extracellular matrix. It is becoming increasingly apparent that molecular interactions between epithelial cells and cells in the surrounding stroma promote growth, invasion and spread of the tumor itself and thus represents a crucial underlying driving force in tumorigenesis. AREAS COVERED: This article reviews how key interactions between tumor epithelial cells and surrounding mesenchymal and immune cells can promote tumor progression and highlights molecular elements that might represent novel therapeutic targets. EXPERT OPINION: The tumor microenvironment is increasingly being viewed as a potential therapeutic target with a number of strategies being developed to disrupt tumor-stroma interactions, in order to delay or circumvent tumor progression. Targeting elements of the tumor microenvironment, or signaling pathways in tumor cells activated as a consequence of stromal interactions, may prove a useful therapeutic strategy to prevent tumor development and progression. However, given the tumor cells' ability to circumvent various therapeutic agents when given as monotherapy, the success of these agents is likely to be seen when used in combination with existing treatments.

Entities:  

Mesh:

Year:  2011        PMID: 21388336     DOI: 10.1517/14728222.2011.561201

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  17 in total

Review 1.  Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.

Authors:  Samuel S Linton; Samantha G Sherwood; Kelly C Drews; Mark Kester
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-07-07

2.  Periostin, a stroma-associated protein, correlates with tumor invasiveness and progression in nasopharyngeal carcinoma.

Authors:  Meixiang Li; Cui Li; Danjuan Li; Yuanjie Xie; Jinfeng Shi; Guoqing Li; Yongjun Guan; Maoyu Li; Pengfei Zhang; Fang Peng; Zhiqiang Xiao; Zhuchu Chen
Journal:  Clin Exp Metastasis       Date:  2012-06-17       Impact factor: 5.150

Review 3.  Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects.

Authors:  Carl N Sprung; Alesia Ivashkevich; Helen B Forrester; Christophe E Redon; Alexandros Georgakilas; Olga A Martin
Journal:  Cancer Lett       Date:  2013-09-14       Impact factor: 8.679

Review 4.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

Review 5.  Cancer research in need of a scientific revolution: Using 'paradigm shift' as a method of investigation.

Authors:  Didier Wion; Florence Appaix; Meriwether Burruss; Francois Berger; Boudewijn van der Sanden
Journal:  J Biosci       Date:  2015-09       Impact factor: 1.826

Review 6.  Role of oxidative stress and the microenvironment in breast cancer development and progression.

Authors:  Agnieszka Jezierska-Drutel; Steven A Rosenzweig; Carola A Neumann
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 7.  Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature.

Authors:  Shujing Shi; Longbang Chen; Guichun Huang
Journal:  Med Oncol       Date:  2013-08-28       Impact factor: 3.064

8.  MS4A1 dysregulation in asbestos-related lung squamous cell carcinoma is due to CD20 stromal lymphocyte expression.

Authors:  Casey M Wright; Santiyagu M Savarimuthu Francis; Maxine E Tan; Maria U Martins; Clay Winterford; Morgan R Davidson; Edwina E Duhig; Belinda E Clarke; Nicholas K Hayward; Ian A Yang; Rayleen V Bowman; Kwun M Fong
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

9.  Systems analysis of a mouse xenograft model reveals annexin A1 as a regulator of gene expression in tumor stroma.

Authors:  Ming Yi
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Authors:  Stephen Hiscox; Bedanta Baruha; Chris Smith; Rebecca Bellerby; Lindy Goddard; Nicola Jordan; Zaruhi Poghosyan; Robert I Nicholson; Peter Barrett-Lee; Julia Gee
Journal:  BMC Cancer       Date:  2012-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.